We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The clinical presentation and outcomes of COVID-19 in immunocompromised hosts in comparison to comorbid and immunocompetent patients: retrospective study of 384 cases.
- Authors
Karimov, Ziya; Huseynova, Gunay; Kiris, Hakan Turan; Tongel, Cansu; Aliyeva, Aynur; Soyer, Nur; Abdullayeva, Nigar; Unat, Omer Selim; Basoglu, Ozen Kacmaz; Sayiner, Abdullah; Tasbakan, Mehmet Sezai
- Abstract
Aim: Immunocompromised hosts (ICH) are at a higher risk of severe infections and mortality. This study aimed to examine the clinical manifestations and outcomes of ICH who were admitted to the hospital for COVID-19. Materials and Methods: A total of 384 patients (mean age 61.5±15.9 y, 168 female) who were hospitalized between March 2020 and December 2020 were included in the study. These patients were examined in three groups: the ICH (n=40), comorbid patients (n=101), and the control group comprising immunocompetent patients without any comorbidities (n=243). All clinical and laboratory data were retrieved from the electronic hospital records and compared between the three groups retrospectively. Results: The mean age was 61.2±15.0 for ICH, 66.1±12.3 for comorbid, and 59.6±17.0 for control groups (p=0.003). We found that the mean leukocyte and neutrophil counts, C-reactive protein (CRP), ferritin, and D-Dimer levels were significantly higher, and the albumin level was lower in ICH compared to the other two groups (p<0.05). On CT scans, ground-glass opacities were seen less frequently in ICH compared to the other groups (p=0.035). The mortality rate was 32.5% in the ICH, 22.8% in the comorbid, and 15.2% in the control groups (p=0.019). Within the ICH group, the mean leukocyte, and neutrophil counts and LDH levels were higher and the SpO2/FiO2 ratio was lower in patients who died (p<0.05). Conclusion: We found that had higher mortality in ICH with COVID-19. Being ICH condition, elder age, elevated LDH levels, and decreased Sat/FiO2 were associated with increased mortality.
- Subjects
COVID-19 pandemic; IMMUNOCOMPROMISED patients; MORTALITY; HOSPITAL records; HEALTH outcome assessment
- Publication
Ege Journal of Medicine, 2024, Vol 63, Issue 2, p192
- ISSN
1016-9113
- Publication type
Article
- DOI
10.19161/etd.1256543